Artiva Biotherapeutics Ends AlloNK Program, Shares Slide
Artiva Biotherapeutics pulled the plug on its lead development candidate, AlloNK, and said it would explore alternatives to maximize shareholder value. Shares fell sharply Tuesday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.